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Introduction
Allogeneic hematopoietic cell transplantation (HCT) is the most validated immunotherapy able to cure 
hematological malignancies via the graft-versus-leukemia (GVL) activity of  donor T cells (1, 2). Unfortu-
nately, donor T cells also mediate damage to normal host tissues, potentially leading to acute graft-versus-
host disease (aGVHD). aGVHD is currently diagnosed according to clinical symptoms and eventually 
confirmed by biopsies of  the main target organs: skin, liver, and gastrointestinal (GI) tract (3–5). GI-GVHD 
specifically is an often fatal complication of  HCT (6, 7), for which no prognostic blood biomarkers have 
been validated. Although several markers have been identified at the onset of  GVHD and statistical scores 
have been developed based on markers measured upon the occurrence of  clinical signs (8–14), only 2 
markers so far (suppression of  tumorigenicity 2 [ST2] and T cell immunoglobulin and mucin domain–con-
taining 3 [TIM3]) were measured at day 14 after HCT and can be considered as potential early prognostic 
markers that predict the risk of  future development of  aGVHD and nonrelapse mortality (NRM) (10, 12). 
In contrast, regenerating islet-derived 3-α (REG3α), a GI-GVHD marker, is secreted by Paneth cells in 
the intestinal crypts and traverses into the bloodstream following damage to the intestinal mucosa barrier, 
suggesting that REG3α secretion is a relatively late event in GVHD (9, 12). Thus, the need for the discovery 
and validation of  additional early GI-GVHD prognostic markers still exists.
In the present study, we sought to identify an early GI-GVHD marker using in-depth proteomic pro-
filing. Here, we present the discovery of  2 proteins, CD146, and the chemokine CCL14 as well as a pop-
ulation of  T cells expressing both CD146, which binds to other CD146 molecules through homophilic 
Gastrointestinal graft-versus-host-disease (GI-GVHD) is a life-threatening complication occurring 
after allogeneic hematopoietic cell transplantation (HCT), and a blood biomarker that permits 
stratification of HCT patients according to their risk of developing GI-GVHD would greatly aid 
treatment planning. Through in-depth, large-scale proteomic profiling of presymptomatic samples, 
we identified a T cell population expressing both CD146, a cell adhesion molecule, and CCR5, 
a chemokine receptor that is upregulated as early as 14 days after transplantation in patients 
who develop GI-GVHD. The CD4+CD146+CCR5+ T cell population is Th17 prone and increased by 
ICOS stimulation. shRNA knockdown of CD146 in T cells reduced their transmigration through 
endothelial cells, and maraviroc, a CCR5 inhibitor, reduced chemotaxis of the CD4+CD146+CCR5+ T 
cell population toward CCL14. Mice that received CD146 shRNA–transduced human T cells did not 
lose weight, showed better survival, and had fewer CD4+CD146+CCR5+ T cells and less pathogenic 
Th17 infiltration in the intestine, even compared with mice receiving maraviroc with control shRNA–
transduced human T cells. Furthermore, the frequency of CD4+CD146+CCR5+ Tregs was increased in 
GI-GVHD patients, and these cells showed increased plasticity toward Th17 upon ICOS stimulation. 
Our findings can be applied to early risk stratification, as well as specific preventative therapeutic 
strategies following HCT.
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interaction, and CCR5, the chemokine receptor of  CCL14. CD146 is a cell adhesion molecule expressed 
at the intercellular junction of  endothelial cells (ECs) and is therefore involved in heterophilic cell-cell 
interactions and angiogenesis (15, 16). CD146 expression has been shown to be higher in intestinal biopsies 
from patients with inflammatory bowel disease (17, 18). Human CD146 is also expressed on a small subset 
of  effector memory T cells (19–22) and, through CD146-CD146 interactions, may recruit activated T cells 
to inflammation sites (23, 24). CCL14 is a recently identified chemokine constitutively expressed in many 
tissues, including normal and inflamed intestinal epithelial cells, and is a ligand of  the chemokine receptor 
CCR5 expressed on T cells (25–28). CCR5 has been shown to be required for T cell migration into inflamed 
intestine in experimental models of  GVHD and human alloreactions (29–31), and its blockade with mar-
aviroc, a CCR5 small molecule inhibitor, prevented visceral GVHD in a clinical trial (32). In the present 
study, we applied proteomic profiling of  presymptomatic GI-GVHD samples to identify potential soluble 
candidate proteins, which led to the discovery of  CD146 and CCL14. Then, we tested the hypothesis that T 
cells exhibiting increased expression of  their receptors (CD146 and CCR5), individually or in combination, 
could serve as cellular markers of  GI-GVHD.
Identification of  early cellular GI-GVHD biomarkers could be translated into clinical utility in pre-
dicting higher risk of  developing GI-GVHD and subsequent NRM, which would allow for the application 
of  preventative therapeutic strategies following HCT. In addition, such markers may or may not reflect 
the pathophysiology of  GI-GVHD, and the second goal of  our study was to explore this aspect. Finally, 
if  the identified markers happen to be activation markers expressed on T cells, they could represent novel 
druggable targets.
Results
Proteomics analysis of  presymptomatic GI-GVHD. To discover GI-specific candidate proteins prior to GVHD 
onset, we applied in-depth quantitative proteomics as previously described (9, 10, 33). Patient samples 
were collected prospectively before the onset of  GVHD symptoms and then selected based on patients’ GI- 
GVHD statuses. We compared pooled plasma taken 14 days prior to clinical manifestations from 10 patients 
who later developed GI-GVHD (labeled with a heavy isotope) and 10 controls without GVHD at matched 
time points (labeled with a light isotope). The isotopes allowed for comparison of  relative concentrations 
of  proteins between the groups. The 2 pools were subjected to tandem mass spectrometry. We then selected 
candidate proteins showing at least 1.5-fold greater expression in GI-GVHD samples versus non-GVHD 
samples (Supplemental Table 1; supplemental material available online with this article; doi:10.1172/jci.
insight.86660DS1) that were not previously identified in proteomics experiments performed with the same 
platform and for which antibodies to their cellular receptors were available if  an ELISA kit was not avail-
able. Two lead proteins emerged: (i) CD146, a cell adhesion molecule expressed on ECs particularly during 
inflammation (18) and on a subset of  activated T cells (20, 22, 34), allowing their entry into the intestine 
through homophilic CD146-CD146 interactions (23, 24); and (ii) CCL14 that binds to the T cell chemokine 
receptor CCR5 (25, 26), which is known to facilitate T cell infiltration into the intestine (29, 30) and for 
which trafficking can be blocked by a CCR5 small molecule inhibitor in GI-GVHD patients (32).
Because these proteins had not been previously identified in proteomics experiments and antibodies 
for their receptors on T cells were available, we analyzed their expression profiles on peripheral blood (PB) 
cells from 214 HCT patients (93 with GI-GVHD [including patients who experienced GI-GVHD after skin 
GVHD], 48 without GVHD, 33 with non-GVHD enteritis, and 40 with skin GVHD) at the onset of  symp-
toms at a median of  29 days after HCT or at similar time points from patients with non-GVHD enteritis or 
without GVHD. We used the same cohort as the published REG3α study (9), including patients who had 
PB cells available. Briefly, the cohort consisted of  4 groups: patients with newly diagnosed GVHD involv-
ing the GI tract (with or without other organ involvement) (GI-GVHD); patients tested at similar time 
points who never developed GVHD symptoms (no GVHD); patients with GI distress that was inconsistent 
with GVHD either by clinical or histologic criteria (non-GVHD enteritis); and patients who presented 
with isolated skin GVHD (skin GVHD). PB samples were collected at the time of  symptoms in a time 
frame of  48 hours before or after treatment and at similar times after HCT in patients without GVHD. We 
also added phenotyping prior to GI-GVHD or non-GVHD enteritis for those patients with PB samples 
and enough cells available. Of  note, the cohort is smaller, as PB cells were not collected when the patients 
were seen in the outpatient clinic, whereas plasma samples were. The patient characteristics are summa-
rized in Supplemental Table 2. The causes of  non-GVHD enteritis are detailed in Supplemental Table 3. 
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Conventional T cells were defined as CD4+CD25loCD127+ (see gating strategy in Supplemental Figure 1). 
The frequency of  CD4+CD146+CCR5+ T cells was greater in GI-GVHD patients than in patients without 
GVHD, with non-GVHD enteritis, or with skin GVHD (Figure 1, A and B). In addition, the absolute 
lymphocyte counts (ALCs) did not differ between groups, and the absolute count of  CD4+CD146+CCR5+ 
T cells was highly correlated to the CD4+CD146+CCR5+ T cell frequency in the whole cohort (Spearman 
r = 0.63, P < 10–4, Supplemental Figure 2). The frequency of  T cells expressing only CD146 followed the 
same trend as the CD4+CD146+CCR5+ T cells with slightly less significance (Supplemental Figure 3A), 
whereas the frequency of  CD4+ T cells expressing only CCR5, although different between the GI-GVHD 
and non-GVHD enteritis groups, was not different between the GI-GVHD and no GVHD or skin GVHD 
groups (Supplemental Figure 3B). The CD8+ T cells in GI-GVHD patients did not express enough detect-
able CD146 (lower than that in healthy donors) for interpretation as cellular marker (Supplemental Figure 
4). The CD4+CD146+CCR5+ T cell frequency discriminated GI-GVHD from non-GVHD enteritis with 
an AUC of  0.84, which was more robust than the AUC of  0.79 obtained using the CD4+CD146+ T cell 
frequency (Supplemental Figure 5 and not shown). These data suggest that the CD4+CD146+CCR5+ T cell 
frequency, better than the CD4+CD146+ T cell frequency, could be used as a possible diagnostic marker of  
GI-GVHD, particularly in comparison with non-GVHD enteritis, an often challenging clinical dilemma.
CD4+CD146+CCR5+ T cells and patient outcomes. The strength of a marker is enhanced if  it can be used not 
only for diagnosis but to predict patient outcomes. Therefore, we investigated whether the CD4+CD146+CCR5+ 
T cell frequency correlated with maximum GVHD severity or the 6-month NRM from the time the blood sam-
ple was drawn. The CD4+CD146+CCR5+ T cell frequency measured at GVHD onset was greater in patients 
who eventually developed GI-GVHD of maximum severity (Supplemental Figure 6). We next analyzed the 
impact of the CD4+CD146+CCR5+ T cell frequency on the 6-month NRM in all patients with symptoms 
(GI-GVHD, non-GVHD enteritis, and skin GVHD). We found that the median CD4+CD146+CCR5+ T cell 
frequency in patients with GI-GVHD (2.3%) could be used as a cut point for the risk of NRM within 6 months 
from the sample draw, with 39.6% of patients in the high-risk group experiencing NRM compared with only 
11.5% of patients in the low-risk group (P = 0.001, Figure 1C). In contrast, the incidence of relapse mortality 
was comparable in the groups (Figure 1D). Moreover, the 6-month event-free survival rates were 42.8% and 
64.6% among patients with high and low CD4+CD146+CCR5+ T cell counts, respectively (P = 0.002, Figure 
1E), suggesting that the CD4+CD146+CCR5+ T cell count has prognostic value.
CD4+CD146+CCR5+ T cells circulate before GI GVHD onset. A new risk factor improves diagnostic power 
only if  it does not correlate with other known markers. Our previous proteomics experiments revealed cor-
relations between REG3α and ST2 with GI-GVHD (9, 10), but here we found that these markers were not 
highly correlated with the CD4+CD146+CCR5+ T cell population (Supplemental Figure 7A). We also ana-
lyzed the CD4+CD146+CCR5+ T cell frequency in patients categorized according to the localization of  GI 
symptoms: diarrhea versus nausea/vomiting. The double-positive T cell population distinguished GI-GVHD 
from non-GVHD enteritis regardless of  symptom localization, suggesting the CD4+CD146+CCR5+ T cell 
subset appears early in the GVHD process, given that nausea/vomiting symptoms usually precede diarrhea 
symptoms (Supplemental Figure 7B). Furthermore, the CD4+CD146+CCR5+ T cell frequency was not cor-
related with GI histologic severity, suggesting that these cells are not a product of  mucosa damage but rather 
systemic effectors (Supplemental Figure 7C). Based on these observations and the identification of  CD146 
and CCL14 in proteomics analysis of  samples collected prior to the onset of  clinical signs, we next explored 
the prognostic value of  the CD4+CD146+CCR5+ T cell frequency using 31 paired samples collected before 
GI-GVHD at a median of  19 days after transplantation and at onset of  GI-GVHD. The CD4+CD146+CCR5+ 
T cell population was found to circulate in PB at a median interval of  14 days prior to the occurrence of  
Figure 1. A CD4+CD146+CCR5+ T cell population in allogeneic HCT patients at GVHD onset and prior to GVHD onset. (A) Representative plots showing CCR5 
and CD146 expression in samples from patients with GI-GVHD, without GVHD, with non-GVHD enteritis, and with skin GVHD. (B) CD4+CD146+CCR5+ T cell 
frequencies in healthy donors (HD), autotransplant patients (Auto), and allogeneic patients. n and median post-HCT onset of signs or samples are shown 
below the graphs. The data are shown as mean ± SEM, 2-tailed Student’s t tests. (C) Six-month nonrelapse mortality since sample draw in allogeneic HCT 
patients with symptoms (GI-GVHD, non-GVHD enteritis, and skin GVHD, n = 166) divided by low and high CD146+CCR5+ T cell frequencies. High-risk group in 
red (CD4+CD146+CCR5+ T cell frequency ≥ 2.3%, n = 51) and low-risk group in blue (CD146+CD146+CCR5+ T cell frequency < 2.3%, n = 115), P = 0.001, calculated 
for the overall curve. (D) Six-month relapse mortality since sample draw in the same population, P = 0.64. (E) Six-month event-free survival since sample 
draw in the same population, P = 0.002. (F) CD4+CD146+CCR5+ T cell frequency in paired samples prior to GVHD onset in GI-GVHD patients (n = 31) with 
a median interval of 14 days between the first measurement and measurement at onset of disease and at matched time points in non-GVHD enteritis 
patients (n = 7), paired t test analysis. Cumulative incidence (C and D) and Kaplan-Meier analysis (E) used.
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Figure 2. Th17-prone CD4+CD146+CCR5+ T cell population. (A) Differential transcriptomes in CD146+CCR5+ Tcons versus Tcons excluding this population. (B) 
RORC and IL-17 expression in patients’ samples (n = 35 and 41, respectively). (C) Th1 or Th17 differentiation of naive T cells with anti-CD3/CD28 stimula-
tion. Representative plots showing CD146 expression in CD4+ T cells and a dot plot depicting mean ± SEM values for frequency of CD146 (n = 16), 2-tailed 
Student’s t test. (D) Th1 or Th17 differentiation of naive T cells with anti-CD3/CD28 or anti-CD3/ICOS stimulation. Representative plots of CD146 and CCR5 
expression and a dot plot depicting mean ± SEM values for frequency of CD4+CD146+CCR5+ T cells (n = 4), 2-tailed Student’s t test. (E) Representative plots 
showing IL-17 and IFN-γ coexpression in CD4+ T cells and a dot plot depicting mean ± SEM values for frequency of IL-17+IFN-γ+ T cells in the same 4 condi-
tions as in E (n = 7), 2-tailed Student’s t test.
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GI-GVHD symptoms at a frequency not significantly different from that at onset, whereas the frequency 
of  CD4+CD146+CCR5+ T cells was not increased in non-GVHD enteritis patients at a median interval of  
14 days prior to the occurrence of  non-GVHD diarrhea symptoms (Figure 1F). We also analyzed the CD4+ 
CD146+CCR5+ T cell frequency in GI-GVHD patients over time after sampling (samples for 93 patients were 
collected at onset, and preonset samples for 31 patients were collected at time points between days 14 and 92 
after HCT) and found no indication that this population varies over time in the blood of  patients. Interest-
ingly, 6 values over 10% were observed between days 19 and 27 after HCT (Supplemental Figure 8).
CD4+CD146+CCR5+ T cells are Th17 prone. We then characterized the CD4+CD146+CCR5+ T cell popula-
tion and defined differential transcriptomes between sorted CD4+CD146+CCR5+ T cells and T cells exclud-
ing this population (Supplemental Table 4). Transcription of  RAR-related orphan receptor C (RORC), a 
transcription factor essential for Th17 development, was upregulated 4-fold, and this upregulation was con-
firmed at the protein level by intracellular staining of  RORC and IL-17 in patient samples (Figure 2, A and 
B). Intracellular staining for Th1-transcription factor TBET in the same patient samples did not indicate 
Figure 3. Endothelial CD146 expres-
sion in GI-GVHD colonic biopsies, 
transendothelial migration of 
CD4+ T cell subsets and with CD146 
knockdown, and chemotaxis of 
CD4+CD146+CCR5+ T cells. (A) Immu-
nohistochemical analysis of CD146 
expression in colonic biopsies taken at 
onset of symptoms from non-GVHD  
enteritis patients and GI-GVHD 
patients (magnification ×200). Dot 
plot showing mean ± SEM values for 
CD146+ vessel counts ×10, 2-tailed 
Student’s t test from non-GVHD 
enteritis patients (n = 10) and GI-GVHD 
patients (n = 18). (B–E) Transen-
dothelial migration of CD146– and 
CD146+ T cells sorted from PB cells, 
Th1 and Th17 cells, Th17 cells with 
CD146 knockdown via CD146 shRNA1, 
or CD146 shRNA2. Representative 
flow cytometric histograms showing 
the efficiency of CD146 knockdown. 
Isotype control staining (gray) and 
CD146 staining of cells with the control 
shRNA (red) and CD146 shRNA (blue). 
Dot plots show mean ± SEM values 
for percentage of transmigrated CD4+ 
T cells (n = 6 for B, n = 5 for C, n = 5 for 
D, and n = 8 for E), 2-tailed Student’s 
t test. (F) CCR5-mediated chemotaxis 
of CD4+CD146+CCR5+ T cells toward 
CCL14 or CCL14 and CCL5. The sorted 
double-positive cells were pretreated 
with maraviroc (MV) or vehicle control. 
Data are presented as mean ± SEM 
values (n = 3), paired t test.
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significant upregulation (Supplemental Figure 9). The CD4+CD146+CCR5+ T cell population is also char-
acterized by an effector memory phenotype defined by the absence of  CD45RA and CCR7 (35) as com-
pared with the T cell population excluding the double-positive population (Supplemental Figure 10). In the 
same transcriptomic profile, we looked at 9 Th17 stemness transcripts (36, 37) in the CD4+CD146+CCR5+ 
T cells versus T cells excluding this population and found no significant differences (Supplemental Table 5).
Figure 4. Donor human T cells with CD146 knockdown in a xenogeneic GVHD model. (A) Body weight loss of NSG mice transplanted with lentivirally 
transduced human CD4+ T cells. Control shRNA group (n = 8) and CD146 shRNA group (n = 9), 2-tailed Student’s t test. (B) Kaplan-Meier survival curves. 
Control shRNA group (n = 30) and CD146 shRNA group (n = 27), log-rank test. (C) Human CD4+ T cell engraftment in spleen, (D) CD4+CD146+CCR5+ T cell 
frequency in the gut, and (E) Th17 cells coexpressing IL-17 and IFN-γ in the spleen. Mice were analyzed between days 30–45 after transplantation for C–E. 
Representative flow cytometric plots at the top and dot plots showing mean ± SEM values at the bottom, 2-tailed Student’s t test. The data in C and 
D were from 10 mice per group. The data in E were from 5 mice in the control group and 4 mice in the CD146 group. (F) Body weight loss and (G) survival 
curves of NSG mice transplanted with CD146 shRNA or control shRNA lentivirus and treated with maraviroc (MV) or vesicle control, 2-tailed Student’s t 
test for weight loss between control shRNA vs. control shRNA + MV and log-rank test for survival (n = 12 per group). (H) Human T cell infiltration in the 
gut of mice receiving transduced CD4+ T cells and MV or vehicle control. Mice were analyzed at day +35 after transplantation (n = 5 per group), 2-tailed 
Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001.
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Consistent with data from patient samples, CD146 expression in in vitro Th17-differentiated cells was 
3-fold greater than in Th1-differentiated cells (Figure 2C). We also verified that CD4+CD146+CCR5+ T 
cells were induced upon allogeneic reactivity (Supplemental Figure 11). ICOS stimulation is critical for the 
development of  human Th17 cells (38), and we found that ICOS stimulation and Th17 differentiation con-
ditioning induced the CD4+CD146+CCR5+ population (Figure 2D). CCR5 expression was not upregulated 
after activation by CD28 costimulation, which is consistent with previous findings (39). Importantly, this 
conditioning also increased the number of  cells coexpressing IL-17/IFN-γ (Figure 2E).
Other Th17 markers, such as CD161, IL-23R, and CXCR6 (40–44), were all expressed at higher levels 
in T cells differentiated with Th17 conditioning and ICOS (Supplemental Figure 12A). Furthermore, we 
analyzed the following Th17 markers — IL-17/IFN-γ, GM-CSF, IL-22, CCR4, CCR6, CD161, CXCR6, 
and IL-23R — in the double-positive T cells as compared with the T cells excluding this population (Sup-
plemental Figure 12B). Overall, these data show that the CD4+CD146+CCR5+ T cell population is Th17 
prone and increased by ICOS stimulation, linking these cells to two known driving forces for the induc-
Figure 5. CD146+CCR5+ Tregs in allogeneic HCT patients 
at GVHD onset and ICOS-induced CD146+CCR5+ Tregs. 
(A) CD146+CCR5+ Treg frequencies in HCT patients. n and 
median post-HCT onset of signs or samples are shown 
below the graphs. The data are shown as mean ± SEM, 
2-tailed Student’s t test. (B) Differential transcriptomes 
in sorted CD146+CCR5+ Tregs vs. Tregs excluding this 
population. (C) Representative plots showing CD146 
and CCR5 expression in Tregs stimulated with anti-CD3/
CD28 or anti-CD3/ICOS beads, and a dot plot depicting 
mean ± SEM values for frequency of CD146+CCR5+ Tregs 
(n = 3), 2-tailed Student’s t test. (D) Representative 
plots showing IL-17 and IFN-γ coexpression in Tregs, and 
a dot plot depicting mean ± SEM values for frequency 
of IL-17+IFN-γ+ T cells in the same 2 conditions as in C 
(n = 3), 2-tailed Student’s t test. (E) Representative 
plots showing FOXP3 expression in Tregs stimulated 
with anti-CD3/CD28 or anti-CD3/ICOS beads, and a dot 
plot depicting mean ± SEM values for normalized mean 
fluorescence intensity (MFI) of the Tregs (n = 4), 2-tailed 
Student’s t test. Isotype control staining in gray.
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tion and amplification of  the GVHD effector phase, which results in direct and indirect damage to host 
cells. Importantly and consistent with patient data, ICOS signaling did not induce significantly more 
CD8+CD146+CCR5+ T cells than did CD28 signaling (Supplemental Figure 13A), which was in contrast 
to ICOS-induced generation of  CD4+CD146+CCR5+ T cells from conventional T cells (Tcons) (Supple-
mental Figure 13B). Together, our data are consistent with previously published findings demonstrating the 
involvement of  Th17 cells in the pathogenesis of  GI-GVHD (45–48).
Because it is technically impossible to sort enough double-positive cells from a single healthy donor 
buffy coat to perform functional experiments (mean ± SEM: 0.10% ± 0.02% of  total cells or 0.26 ± 0.15 
million CD4+CD146+CCR5+ T cells, n = 5), and because the total CD4+CD146+ T cell population is suf-
ficiently correlated with the double-positive T cell population, we performed additional experiments on 
sorted CD146+ T cells (0.64% ± 0.09% of  total cells or 1.53 ± 0.44 million CD4+CD146+ T cells after sort-
ing from a single healthy donor buffy coat, n = 11), we focused on CD146+ T cells for functional and in vivo 
studies. For this purpose, we analyzed their phenotype and found that mature CD146+ T cells expressed 
equivalent amounts of  IL-17 after in vitro differentiation under Th1 or Th17 conditions with CD28 or 
ICOS costimulation (Supplemental Figure 14). This result suggested that they are antigen experienced and 
Th17 prone before they acquire the CCR5 surface antigen and they could be used as a surrogate cell type 
for CD4+CD146+CCR5+ T cells in efforts to decipher their mechanism in vitro.
CD146 endothelial expression is increased in GI-GVHD biopsies and Th17-polarized CD146 T cells preferentially 
migrate through the activated endothelium. Because the CD4+CD146+CCR5+ T cell population circulates early 
after HCT and endothelial CD146 is overexpressed during inflammation (18), we hypothesized that, in 
response to transplant conditioning and cytokine release, alloreactive T cells express the double-positive 
population in parallel to increased CD146 expression in the intestinal endothelium and increased CCL14 
release from the epithelium. This would allow CD4+CD146+CCR5+ T cells to transmigrate across the endo-
thelium via CD146-CD146 interaction and then to come in contact with the intestinal epithelium through 
chemotaxis to CCL14. To test the hypothesis that CD146 and CCL14 are upregulated in GVHD-activated 
intestine, we stained colonic biopsies of  patients with non-GVHD enteritis and GI-GVHD for CD146 and 
CCL14. Significantly greater CD146 expression was observed on the endothelium of  GI-GVHD patients 
(Figure 3A), and CCL14 expression also was increased in GI-GVHD, although not significantly (Supple-
mental Figure 15). Of  note, CD3+CD146+ expression on T cells was not significantly altered (Supplemental 
Table 6). These results suggest that both endothelial and lymphocytic CD146 could play an important role 
in recruiting pathogenic T cells to the intestine. If  our hypothesis is true, more CD146+ and Th17-differ-
entiated T cells should transmigrate through the activated endothelium as compared with CD146– and 
Th1 cells. Indeed, more CD146+ or Th17 cells migrated through TNF-α–activated ECs in transwell assays 
(Figure 3, B and C). Lentivirally induced shRNA knockdown of  CD146 in CD4+ T cells led to a significant 
reduction in T cell transmigration (Figure 3D). To eliminate possible off-target effects, we verified these 
results with a second shRNA (Figure 3E). However, siRNA knockdown of  CD146 on ECs did not reduce 
T cell transmigration (not shown), suggesting that CD146 on T cells, but not on ECs, is a key promoter of  
pathogenic T cell infiltration into GVHD target organs.
CD4+CD146+CCR5+ T cells show increased chemotaxis toward CCL14 that is inhibited by maraviroc. We next 
evaluated the chemotaxis of  CD4+CD146+CCR5+ T cells to CCL14. CCR5 on T cells can bind both CCL14 
and CCL5, but only CCL14 was identified in the proteomics experiment. Thus, we tested the chemotaxis 
of  CD4+CD146+CCR5+ T cells to CCL14 and CCL14+CCL5+ T cells. Chemotaxis of  CD4+CD146+CCR5+ 
T cells was significantly increased toward CCL14 and even more so toward both CCL14+CCL5+ T cells. 
This chemotaxis was inhibited by the CCR5 inhibitor maraviroc (Figure 3F), and this inhibition was simi-
lar to that previously shown with T lymphoblasts (28).
CD146 shRNA–transduced T cells reduce xenogeneic GI-GVHD. To evaluate the in vivo role of  CD146 on T 
cells, we first used CD146 KO T cells in allogeneic murine GVHD models. Transfer of  CD146 KO T cells 
had not previously been used in immune-mediated disease models. Unfortunately, the GVHD severity did 
not differ upon transplantation of  these cells versus WT T cells (Supplemental Figure 16, A and B), which 
may be due to the low expression of  CD146 on donor murine T cells compared with human T cells (Sup-
plemental Figure 16C) as previously shown (49). We therefore transplanted donor human CD4+ T cells, 
which express approximately 2% of  CD146 (19) before lentiviral transduction, with CD146 knockdown 
achieved via lentiviral shRNA in the xenogeneic mouse GVHD model. CD146 expression in transduced 
CD4+ T cells was significantly knocked down by the CD146 shRNA both at the time of  transplantation and 
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at day 45 after transplantation (Supplemental Figure 17). In comparison with the control group, immuno-
deficient NOD/scid/IL-2Rγ−/− (NSG) mice transplanted with CD146 shRNA–transduced T cells did not 
lose weight (Figure 4A), had better survival (Figure 4B), showed similar human T cell engraftment (Figure 
4C), had fewer CD4+CD146+CCR5+ T cells in the intestine (frequencies and absolute counts, Figure 4D 
and Supplemental Figure 18, respectively), and had fewer IL-17/IFN-γ–coexpressing T cells (Figure 4E). 
We could not technically transfer double CD146 and CCR5 shRNA–transduced T cells; however, we next 
attempted to test the role of  CCR5 inhibition by using the CCR5 inhibitor maraviroc in the xenogeneic 
model, as has been done in patients (32). We also compared its action with the control shRNA–trans-
duced T cells and the CD146 shRNA–transduced T cells plus maraviroc. NSG mice transplanted with con-
trol shRNA–transduced T cells and treated with maraviroc for 21 days lost less weight than the untreated 
mice transplanted with control shRNA–transduced T cells (Figure 4F), showed improved survival (Fig-
ure 4G), and had less CD4+CD146+CCR5+ T cell gut infiltration (Figure 4H). Transplantation of  CD146 
shRNA–transduced T cells also showed a decrease in the in vivo production of  IL-17/IFN-γ by CD4+ 
CD146+CCR5+ T cells, whereas treatment with maraviroc had no effect on the in vivo production of  IL-17/
IFN-γ by the CD4+CD146+CCR5+ T cells (Supplemental Figure 19). There were no differences in body 
weight, survival, or CD4+CD146+CCR5+ T cell infiltration in the intestine between NSG mice transplanted 
with CD146 shRNA–transduced T cells and those transplanted with CD146 shRNA–transduced T cells 
and treated with maraviroc (Figure 4, F–H), possibly suggesting that CCR5 is acquired by the Th17-prone 
CD146 T cells during GVHD development.
CD4+CD146+CCR5+ Treg frequency is increased in GI-GVHD patients. Tregs are crucial for the inhibition 
of  GVHD development (50). In our study, the frequency of  total Tregs defined by CD25+CD127–FOXP3+ 
on CD4+ T cells (see gating strategy in Supplemental Figure 1) was significantly decreased in GI-GVHD 
patients compared with patients with non-GVHD enteritis (P = 0.006) and patients without GVHD (P 
= 0.04) as previously reported (refs. 51–53 and Supplemental Figure 20). However, the frequency of  
CD146+CCR5+ Tregs was increased in GI-GVHD patients as compared with patients with non-GVHD 
enteritis (P = 0.003) and patients without GVHD (P = 0.005; Figure 5A). We further characterized the 
CD146+CCR5+ Tregs using NanoString analysis and found that, although they still express FOXP3, they 
also express inflammatory molecules such as IL-26, IFN-α, IL-27, IFN-γ, RORC, IL-18, IL-17A, and the 
exhaustion marker PD-1 (Figure 5B and Supplemental Table 7). Expression of  IFN-γ, IL-17, and PD-1 in 
the double-positive Tregs as compared with the Tregs excluding CD146+CCR5+ cells was confirmed at the 
protein level by flow cytometry (Supplemental Figure 21). These data suggest that the CD146+CCR5+ Tregs 
might show increased plasticity toward Th17. To explore this hypothesis, we differentiated human Tregs in 
CD28 or ICOS conditions and found that ICOS stimulation increased the frequency of  CD146+CCR5+ T 
cells (Figure 5C), increased the percentage of  cells coexpressing IL-17/IFN-γ (Figure 5D) among the Tregs, 
and decreased the intensity of  FOXP3 expression (Figure 5E). However, ICOS-expanded Tregs had similar 
suppressive activity as CD28-expanded Tregs (Supplemental Figure 22).
Discussion
The first aim of  this study was to identify proteins and/or cellular risk factors that can predict future GI- 
GVHD and NRM before the development of  symptoms, which would allow preemptive therapy and more 
stringent monitoring in high-risk patients. Equally important to identifying high-risk patients is the identi-
fication of  patients who are at low risk of  developing aGVHD, as these patients could avoid exposure to 
immunosuppressive regimens and thereby experience reduced toxicity. Herein, we used a mass spectrome-
try–based technique to unambiguously identify candidate plasma proteins expressed in GI-GVHD, the pri-
mary cause of  NRM after HCT. Diarrhea is common after HCT and can be caused by a variety of  stimuli, 
but because the consequences of  GVHD are serious, physicians initiate treatment of  suspected GVHD often 
without a bona fide confirmed diagnosis. For the time period before or at the onset of  symptoms of  GVHD 
with GI involvement, the principal findings of  our study are that: (i) measurement of   CD4+CD146+CCR5+ 
T cells and CD146+CD4+ T cells frequencies and counts had prognostic utility in predicting development 
of  GI-GVHD and (ii) predictive value for 6-month NRM and event-free survival. The high frequency of  
CD4+CD146+CCR5+ T cells circulating before the occurrence of  GI symptoms and as early as day 14 after 
HCT suggests that their “expansion” is an early event in the pathogenesis of  GI-GVHD. Furthermore, the 
majority of  patients with paired samples had stable or decreasing frequencies of  CD4+CD146+CCR5+ T 
cells in the blood, which could suggest these cells have already homed to the gut, resulting in their decrease 
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in number in the blood between the two time points (14 days on average). The frequencies of  CD4+ 
CD146+CCR5+ T cells were not correlated with REG3α and ST2, proteins that have been previously linked 
to GI-GVHD development (9, 10), suggesting that this T cell population might be an independent indica-
tor of  GI-GVHD, likely via a different biological mechanism. We believe that our results can improve the 
assessment of  GVHD risk before the development of  clinical signs of  GI-GVHD; however, additional inde-
pendent cohorts will be required to establish the frequency of  CD4+CD146+CCR5+ T cells as a biomarker. A 
generalizable definition of  high risk has yet to be developed and will require larger studies.
The second aim of  this study was to explore whether this T cell population is a mechanistic marker, 
meaning that it is involved in the pathophysiology of  GI-GVHD. First, CD146 was found highly upregu-
lated in GI-GVHD endothelium, which is consistent with findings in other inflammatory GI diseases (17, 
18, 24). We did not observe a clear difference in CD146 expression on the endothelium according to a high- 
or reduced-conditioning regimen–intensity or immune suppression–induced damage among GI-GVHD 
and non-GVHD enteritis colonic biopsies, although we need to be cautious in drawing conclusions due to 
the small sample size. Second, the double-positive T cell population identified in our study traffics more 
efficiently through the endothelium, and our results demonstrate that CD146 on T cells, but not on ECs, 
is a key promoter of  pathogenic T cell infiltration into GVHD target organs. This is in contrast to previous 
findings that targeting endothelial CD146 and not T cells decreases lymphocyte infiltration through the 
blood-brain barrier in an experimental autoimmune encephalomyelitis model (EAE model) or through the 
intestinal endothelium in colitis-associated carcinogenesis (24, 54). In contrast to our original hypothesis, 
our data showed that there are no homophilic CD146-CD146 interactions; thus, the most logical potential 
receptor on the endothelium is laminin-411, as it has been shown to be the vascular ligand for CD146 and 
to facilitate Th17 cell entry in the CNS in EAE (55). Third, the high affinity CCR5 ligand CCL14 tended 
to be increased in GI-GVHD patients’ colonic cells. CCL14 is constitutively expressed and secreted by 
multiple tissues and is present in high concentrations in plasma (25). However, proteolytic processing of  
CCL14 is required to generate high-affinity binding to CCR5 (28), and it is possible that CCL14 is effi-
ciently processed only in the GI tract. Furthermore, we showed that CCR5 played a functional role in driv-
ing chemotaxis of  CD4+CD146+CCR5+ T cells toward CCL14. We also showed that GVHD was improved 
in mice that received maraviroc with shRNA control human T cells but less so in mice that received only 
CD146 shRNA–transduced human T cells. Several studies have explored the role of  CCR5 in alloreactivity 
with data that are either concordant or discordant to our findings as discussed below. In the pathogenesis 
of  human aGVHD, CCR5-mediated alloreactivity on Tcons enhances aGVHD (31), and the CCR5 antag-
onist maraviroc limits GI-GVHD in recipients of  allo-HCT (32). However, in another study using exper-
imental models (29), the authors clearly showed that GVHD occurred more commonly in mice receiving 
CCR5–/– Tregs than in WT mice. Another study showed that the frequency of  high CCR5-expressing Tregs 
was significantly greater in patients without GVHD than in those with GVHD before day 100 (56). Based 
on our data, we believe that the role of  the double-positive CD146+CCR5+ Tregs is important but less 
than the double-positive Tcons because although they are plastic toward Th17, they remain suppressive 
(Supplemental Figure 22). Fourth, we showed that the CD4+CD146+CCR5+ T cell population is Th17 
prone and antigen experienced, which is consistent with previously published reports (45–48). The CD4+ 
CD146+CCR5+ T cell population also displayed a molecular signature of  pathogenic Th17 cells (ref. 44 and 
Supplemental Table 8). Fifth, the role of  ICOS signaling in generating this population must be highlighted. 
ICOS stimulation through ICOS ligands, in concert with the cytokine milieu, critically dictates the fate of  
human Th17 cells (38). Similarly, we found that ICOS stimulation and Th17 differentiation conditioning 
induced the CD146+CCR5+ Tcons that coexpress IL-17/IFN-γ. We also found that CD146+CCR5+ Tregs 
could be induced by ICOS/ICOS ligand signaling and that, as a result, these cells produced IL-17 and 
exhibited decreased FOXP3 expression as described previously (38, 57). These results suggest that these 
Tregs exhibit increased plasticity — flexibility from one Th lineage to the other caused by changes in the 
environment — toward Th17, a phenomenon that is currently widely accepted (58). Based on this finding, 
it would be interesting to determine if  patients with GI-GVHD have antigen-presenting cells (APCs) that 
express ligands for ICOS and CD28 on their cell surface and if  it is due to host preconditioning, cytokine 
release, alloreactivity, and perhaps the microbiome. Indeed, host preconditioning with total body irradia-
tion was recently shown to induce ICOS ligand expression on APCs (59). This requires further exploration 
in experimental models, given that studying recipient antigen presentation in patients is difficult (beyond 
correlative studies that are imperfect).
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Finally, the results of  our study have several therapeutic implications because this population has poten-
tial as a druggable target, such as has been shown recently for the biomarker ST2 (60, 61). Importantly, 
because both CD146+CCR5+ Tcons and Tregs are increased, they can potentially be targetable by the same 
systemic drugs. In addition, because Th17 and IL-17–expressing Tcon (Tc17) induce GVHD without antileu-
kemic effects (62, 63), these interventions should be able to separate GVHD and the graft-versus-tumor 
effect. The first potential target is CCR5. Maraviroc already has been shown to improve GI-GVHD when 
administered in a prophylactic regimen (32). The second potential target is CD146. Human and murine 
anti-CD146 monoclonal antibodies have been used to block CD146 adhesion of  Th17 cells in human brain 
endothelium (64) and in EAE and colitis (24, 54). The third potential target is the IL-17–expressing T cells 
that could be blocked by with either anti–IL-17 antibodies or RORC small molecule inhibitors that can be 
used in both mice and humans. The different mechanisms possibly involved in targeting the IL-17 pathway 
for the prevention of  GVHD have recently been reviewed (65). The fourth potential target is the ICOS/ICOS 
ligand pathway, which can be blocked by anti-ICOS inhibitors. Anti–murine-ICOS has been successfully 
used to alleviate murine GVHD (66) and a syngeneic mouse model of  melanoma transplanted with Tc17 
(59). Different clones of  anti–human-ICOS have been successfully used to ameliorate GVHD in SCID mice 
grafted with human PBMCs (67) and in the context of  tumoral microenvironment (68).
We conclude that early measurement of  the discovered CD4+CD146+CCR5+ T cell population in the 
blood may allow identification of  patients at increased risk for GI-GVHD and thus facilitate preemptive 
intervention via personalized medicine. This ICOS-stimulated, Th17-prone CD4+CD146+CCR5+ T cell 
subset offers opportunities for potential therapeutic targets in GI-GVHD — such as CD146, RORC, and 
ICOS — in addition to the already targetable CCR5 that has been shown to alleviate GVHD (32).
Methods
Patients and samples. Heparinized PB cells were collected weekly during the first 4 weeks and then monthly after 
HCT, as well as at the onset of clinical key events (symptoms of GVHD or skin rash or non-GVHD enteritis).
All patients received pharmacologic GVHD prophylaxis with at least 2 agents, including a calcineurin 
inhibitor (>90% received tacrolimus). PB cells were isolated by density gradient separation and stored fro-
zen at –120°C in liquid nitrogen. All patients received a T-replete graft and GVHD prophylaxis. Samples 
were not analyzed if  methylprednisolone at a dose higher than 1 mg/kg was administered 48 hours or more 
before sample collection. Clinical data abstraction was aided by use of  the electronic medical record search 
engine (EMERSE) (69).
Proteomics work flow. We used an unbiased top-down proteomic approach based on high-resolution 
mass spectrometry (Intact Protein Analysis System) as a discovery engine to identify candidate proteins 
followed by high-throughput sandwich enzyme–linked immunosorbent assay to validate the candidate pro-
teins as reported previously (9, 10, 33)
Multicolor flow cytometry of  patients’ cells. Phenotyping of  cell surface markers on frozen PB cells was per-
formed using antibodies to CD4 (clone OKT4), CD25 (clone 2A3), CD127 (clone HIL-7R-M21), CD146 
(clone P1H12), CCR5 (clone 2D7), CD45RA (clone HI100), and CCR7 (clone 3D12) (all from BD Biosci-
ences). Intracellular staining of  transcription factors (RORC, clone Q21-559, and TBET, clone 4B10) and 
cytokines (IL-17, clone eBio64DEC17, and IFN-γ, clone 4S.B3) was performed after fixation and permea-
bilization according to the manufacturer’s recommendations using the buffer set (eBioscience). Tcons were 
defined as CD4+CD25loCD127+, and Tregs were defined as CD4+CD25+CD127–FOXP3+. Flow cytometric 
analysis was performed using an 8-color Canto II flow cytometer (BD Biosciences) and FlowJo software 
(Tree Star Inc.). Absolute counts of  T cell subsets were calculated by multiplying the frequency of  T cells 
among lymphocytes by the ALC obtained using the automated method.
IHC. Biopsies from GI-GVHD and non-GVHD enteritis patients were obtained per institutional guidelines. 
GVHD was confirmed by duodenal or colonic biopsy in 61 of 71 GI-GVHD patients. Biopsies were graded as 
described previously (70). CD146 and CCL14 monoclonal antibodies (clone sc-374556 and sc-28388, respec-
tively) were purchased from Santa Cruz Biotechnology Inc. Immunostaining was performed by the tissue core 
of the University of Michigan Comprehensive Cancer Center for a subset of 18 GI-GVHD and 10 non-GVHD 
enteritis patients after HCT. All stained GI sections were coded, and 2 pathologists counted positive cells or 
positive blood vessels per ×10 optical field in a blinded manner at ×400 magnification.
Transcriptome analysis after cell sorting. Human leukopaks from healthy donors were purchased from 
the Central Indiana Blood Center under an IRB-approved protocol. PB cells were isolated by Ficoll (GE 
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Healthcare) density gradient centrifugation and stained with fluorescent-conjugated antibodies against 
CD146, CD4, CD8 (clone SK1, eBioscience), CD25, CCR5, and CD127. Stained cells were sorted for 
2 populations (CD146+CCR5+ cells and cells excluding CD146+CCR5+) from the gated Tcons (CD4+ 
CD25loCD127+) or Tregs (CD4+CD25hiCD127–). The nCounter GX Human Immunology Kit (NanoString 
Technologies), which includes more than 500 clinically relevant immune genes, was used in our study. 
NanoString analysis was performed with the nCounter Analysis System.
T cell differentiation. T cells were purified from PB cells prepared from fresh leukopaks as described 
above. Naive CD4+ T cells were negatively selected using a naive CD4+ T cell isolation kit (Miltenyi Bio-
tec). Total CD4+ and CD8+ T cells were isolated using CD4+ or CD8+ T cell isolation kits (Miltenyi Biotec). 
Tcons were positively selected with CD4 microbeads after depletion of  CD25 cells with CD25 microbeads 
(Miltenyi Biotec). CD4+CD146+ and CD4+CD146– T cells were purified using CD146 microbeads (Mil-
tenyi Biotec) from negatively selected total CD4+ T cells. Purified T cells were activated with anti-CD3/
CD28 or anti-CD3/ICOS antibody–coated Dynabeads M-450 Tosylactivated (Invitrogen) at a bead/cell 
ratio of  1:5. For Th1 differentiation, IL-2 (2 ng/ml), IL-12 (10 ng/ml), and neutralizing antibodies against 
IL-4 (10 μg/ml) were added. All antibodies were obtained from eBioscience unless otherwise indicated. 
For Th17 differentiation, IL-1β (20 ng/ml), IL-6 (30 ng/ml), IL-23 (30 ng/ml), TGF-β (2 ng/ml), and 
neutralizing antibodies against IL-4 (5 μg/ml) and IFN-γ (2 μg/ml) were added. Exposure to differentiating 
cytokines (all from R&D Systems) and antibodies was maintained throughout the 7-day culture period.
In vitro Treg stimulation and suppression assays. CD4+CD25+CD127– T cells were purified from PB cells 
prepared from fresh leukopaks using the CD4+CD25+CD127– Regulatory T Cell Isolation Kit II (Miltenyi 
Biotec). For stimulation of  Tregs, 0.1 × 106 T cells were plated in 96-well round bottom plates and stim-
ulated with anti-CD3/CD28 or anti-CD3/ICOS antibody–coated Dynabeads in the presence of  500 U/
ml IL-2. After 8–9 days, the stimulation beads were removed from Tregs before further analysis. For Treg 
suppression assays, 0.1 × 106 CFSE-labeled Tcons were activated with anti-CD3/CD28 beads and cultured 
with or without increasing numbers of  anti-CD3/28 or anti-CD4/ICOS-expanded Tregs. After 3 days, 
proliferation of  the responder Tcons was analyzed by flow cytometry.
Mixed lymphocyte reactions (MLRs). PB cells were prepared from healthy donors. In an allogeneic MLR, 
PB cells from one donor were irradiated at 3,000 cGy and mixed in a 1:1 ratio with PB cells or purified 
CD4+ T cells from another donor. For autologous MLRs, irradiated PB cells were mixed with nonirradi-
ated PB cells from the same donor. Cells were cultured for 8 days before analysis.
Flow cytometry for in vitro assays. Differentiated T cells or MLR cells were analyzed for cell surface expres-
sion of  CD4, CD146, CCR5, CD161 (clone HP-3G10, eBioscience), CXCR6 (clone 56811, R&D Systems), 
and IL-23R (clone 218213, R&D Systems). For intracellular cytokine staining of  IFN-γ, IL-17, IL-22 (clone 
IL22JOP) and GM-CSF (clone DAVKAT) (all from eBioscience), cells were stimulated with PMA (50 ng/
ml; Sigma-Aldrich), ionomycin (1 μg/ml; Sigma-Aldrich), and brefeldin A (3 μg/ml, eBioscience) for 5 hours. 
Intracellular cytokines were stained with an intracellular fixation and a permeabilization buffer set (eBiosci-
ence). Stained cells were analyzed using an Attune Flow Cytometer (Invitrogen) and FlowJo software.
Lentiviral shRNA-mediated knockdown of  CD146 on CD4+ T cells. The pCL2EGw.THPC lentiviral vector 
used to generate CD146 shRNA and control shRNA contains a viral spleen focus forming (SFFV) promoter 
and a histone 1 promoter driving enhanced GFP and shRNA expression, respectively. To generate shRNA 
directed against CD146, the following 3 target sequences of  the human CD146 gene were inserted between 
the Mlu I and Cla I sites of  pCL2EGw.THPC: shRNA1 5′-GGAACTACTGGTGAACTAT-3′, shRNA2 
5′-AGAGCGAACTTGTAGTTGA-3′, and shRNA3 5′-CCAACGACCTGGGCAAAAA-3′, which was 
used as a negative control shRNA because shRNA3 had no effect on CD146 expression on CD4+ T cells.
To produce lentiviral particles, the CD146 shRNA or the control shRNA vector was cotransfected 
with the pCD/NL-BH helper plasmid and the pczVSV-G envelope plasmid into human embryonic kidney 
cells (HEK293T, ATCC, CRL-3216) as described previously (71). To knockdown CD146 expression on 
Th17-differentiated T cells with CD146 shRNA1, naive CD4+ T cells were stimulated with anti-CD3/
CD28 beads under Th17 conditions for 24 hours and transduced with CD146 and control shRNA lentivi-
rus immobilized on Retronectin-coated 24-well plates (72). Beyond 6 days after infection, the Th17 cells 
were restimulated with anti-CD3/CD28 beads under Th17 conditions for 6 more days to achieve maximal 
knockdown. To knock down CD146 expression on Th17-differentiated T cells with CD146 shRNA2, naive 
CD4+ T cells were stimulated with anti-CD3/ICOS beads under Th17 conditions for 24 hours, transduced 
with the CD146 and control shRNA lentivirus, and cultured for 5 additional days. Transduced cells were 
1 4insight.jci.org   doi:10.1172/jci.insight.86660
R e s e a R c h  a R t i c l e
then sorted based on GFP expression and used for in vitro assays. For in vivo functional analysis of  lym-
phocytic CD146, CD4+ T cells were preactivated with anti-CD3/CD28 beads and IL-2 (20 U/ml) for 24 
hours, infected with CD146 and control shRNA lentivirus as described above, and expanded in the pres-
ence of  IL-2 for 4–6 days. Then, GFP-expressing cells were sorted.
siRNA-mediated CD146 knockdown in HUVECs. The Silencer Select siRNA targeting the human CD146 
gene (s8573, sense strand 5′-GGAACUACUGGUGAACUAUtt-3′ and antisense strand 5′-AUAGUU-
CACCAGUAGUUCCtg-3′) and the Silencer Select Negative Control No. 1 siRNA were obtained from 
Invitrogen and transfected into HUVECs using the TransIT-TKO Transfection Reagent from Mirus Bio 
according to the manufacturer’s instructions. The HUVEC line was purchased from ATCC (PCS-100-010). 
Four days after transfection, significant reduction of  CD146 was achieved, and the cells were used for the 
transmigration experiments.
Transmigration assays. The transmigration of  T cells through human microvascular ECs (HMVECs) 
(Lonza Biosciences, CC-2543) was assayed using transwells with a 3-μm pore size (CoStar) and HMVECs 
between passages 7–10. HMVECs (2 × 104) were grown on 50 μg/ml collagen-coated transwell inserts in 
EGM-2MV medium (Lonza Biosciences) for 3 days, followed by treatment with fresh medium containing 
TNF-α (10 ng/ml, Sigma-Aldrich) for 24 hours. FACS-sorted CD146+ and CD146– cells from fresh CD4+ 
T cells among healthy donor PB cells, Th1 cells, or Th17 cells or sorted GFP+ lentivirally transduced Th17 
cells (1 × 105) were added to the top chamber and left to transmigrate through the HMVEC monolayers 
for 24 hours. T cells that migrated to the lower chamber were then collected and counted. The percent that 
transmigrated was calculated as the ratio of  the number of  transmigrated T cells to the number of  input T 
cells × 100. Transmigration experiments were performed in duplicate.
Chemotaxis assay. MLR cultures were stained with antibodies against CD146 and CCR5 (clone 
REA245, Miltenyi Biotec) and sorted for CD4+CD146+CCR5+ T cells. After culture in medium sup-
plemented with 4 U/ml IL-2 overnight, cells were washed and preincubated with the CCR5 antagonist 
maraviroc (10 μM, Selleck Chemicals) or DMSO control for 30 minutes at 37°C in chemotaxis medium 
(RPMI-1640 and 0.5% BSA). Approximately 0.5 × 105 to 1 × 105 cells were added to the top chamber, 
and 600 μl of  chemotaxis medium with or without 100 nM CCL14 (Met-[Gly28-Asn93], BioLegend) 
or a mixture of  CCL14 and 50 nM CCL5 (BioLegend) was added to the bottom chamber of  a 24-well 
Transwell system (polycarbonate filter with 3-μm pore size, CoStar). After incubation for 6 hours at 
37°C, cells from the lower compartment were collected and counted by flow cytometry. Chemotaxis is 
represented as the ratio of  the number of  T cells migrating toward chemokines to the number of  cells 
that underwent spontaneous migration.
CD146 KO donor T cells in murine allogeneic aGVHD models. T cells from the CD146 KO mice and WT 
controls (8–20 weeks of  age) on the H-2b background (73) were provided for this study by Hong Wei Chu 
(National Jewish Health, Denver, Colorado, USA) and used to induce GVHD in 2 established murine 
models as previously described (74). Briefly, Balb/c (H-2d, MHC-mismatched) and C3H.SW (H-2b, minor 
histocompatibility antigen–mismatched) (8–12 weeks of  age) recipient mice received 900 and 1,100 cGy 
irradiation, respectively, on day –1. Recipient mice were injected i.v. with T cell depleted (TCD) BM cells 
(5 × 106) from WT mice together with either WT or KO splenic T cells (1 × 106 WT or CD146 KO B6 T 
cells for Balb/c and 2 × 106 for C3H.SW) on day 0. Mice were housed in sterilized microisolator cages 
and maintained on acidified water (pH < 3) for 3 weeks as described previously (75). Mice were monitored 
for survival daily, assessed for clinical GVHD scores weekly as described previously (76), and euthanized 
when the clinical scores reached 6.
Human-to-mouse xenogeneic model of  GVHD with CD146 or control shRNA knockdown human T cells. Immu-
nodeficient NSG mice (8–14 weeks of  age) were obtained from the In Vivo Therapeutics Core at the Indi-
ana University Simon Cancer Center, housed under specific pathogen-free conditions, and maintained on 
food supplemented with Uniprim and acidic water. All procedures were performed in compliance with 
protocols approved by the institutional animal care and use committee and institutional biosafety commit-
tee. Twenty-four hours after sublethal irradiation at 300–350 cGy, NSG mice were injected i.v. with 1–2 × 
106 sorted human CD4+ T cells lentivirally transduced with the CD146 or control shRNA vector. In some 
experiments, maraviroc dissolved in 2 μl DMSO at a concentration of  100 mg/ml, or an equal volume of  
DMSO alone (vehicle) was diluted in 200 μl PBS and injected into mice i.p. (10 mg/kg) once daily from the 
day before T cell transplantation until 21 days afterward. Mice were monitored daily for survival and scored 
twice per week for GVHD signs as described above.
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Spleen and small and large intestines were harvested from transplanted NSG mice. Single cell suspen-
sion of  spleens was prepared for cell analysis. Single intestinal cells were prepared as previously described 
(60). Cells were stained with Cell Viability Dye (eBioscience), and cell surface staining of  murine CD45 
(clone 30-F11, eBioscience) and human CD4, CD146, and CCR5 or intracellular staining of  IL-17 and 
IFN-γ after PMA and ionomycin stimulation were performed as described above. At day 45 after transplan-
tation, 37.9% ± 2.9% and 11.0% ± 3.7% (n = 10) human CD4+ T cells in the intestines expressed CD146 in 
the control shRNA group and CD146 shRNA group, respectively.
Statistics. Differences in characteristics between patient groups were assessed using Kruskal-Wallis tests 
for continuous values and χ2 tests of  association for categorical values. Frequencies of  T cell subsets were 
compared using 2-tailed Student’s t tests. Receiver operating characteristic (ROC) curves were generated, 
and the AUCs were estimated nonparametrically. The squared Pearson correlation coefficient was used for 
correlation analysis between markers, and the Spearman test was used for correlation between frequencies 
and absolute counts. Differences in immunohistochemical staining of  GI biopsies were calculated using 
the 2-tailed Student’s t test. Event-free survival was estimated using Kaplan-Meier analysis, and NRM 
and relapse mortality (RM) were modeled with cumulative incidence regression methods as described by 
Fine and Gray (77). In vitro data were compared using 2-tailed Student’s t tests or paired t tests for in vitro 
transmigration assays performed with the same donor or 1-way ANOVA. P < 0.05 was considered to be 
statistically significant.
Study approval. The human studies were performed under protocols approved by the University of  
Michigan IRB (2001-0234, study HUM00036058) and after proof  of  informed consent. All animal experi-
ments and euthanasia protocols were approved by the Indiana University School of  Medicine institutional 
animal care committee (IACUC, protocol 10488).
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